Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland

Anne Tscherter; Christina T. Rüsch; Swiss-Reg-NMD group; Dominique Baumann; Cornelia Enzmann; Oswald Hasselmann; David Jacquier; Hans H. Jung; Michelle E. Kruijshaar; Claudia E. Kuehni; Christoph Neuwirth; Georg M. Stettner; Andrea Klein; Nadine Lötscher; Gian P. Ramelli; Paolo Ripellino; Oliver Scheidegger; David Alexander Wille

doi:10.1016/j.nmd.2022.02.001

Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland

Anne Tscherter, Christina T. Rüsch, Swiss-Reg-NMD group, Dominique Baumann, Cornelia Enzmann, Oswald Hasselmann, David Jacquier, Hans H. Jung, Michelle E. Kruijshaar, Claudia E. Kuehni, Christoph Neuwirth, Georg M. Stettner, Andrea Klein^*, Nadine Lötscher, Gian P. Ramelli, Paolo Ripellino, Oliver Scheidegger, David Alexander Wille

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive disorder causing progressive proximal muscular, respiratory, and bulbar weakness. We present outcome data on motor function, ventilation, nutrition, and language development of SMA patients treated with nusinersen in Switzerland. This multicenter, observational study included 44 patients. At treatment initiation, after 2 months and then every 4 months we assessed motor function with the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP–INTEND), Hammersmith Functional Motor Scale expanded (HFMSE) and 6-Minute Walk Test (6MWT). At treatment initiation, patients were 0.1–44.6 years old, treatment duration ranged from 6 to 41 months. All 11 SMA type 1 children achieved higher CHOP-INTEND scores at the last assessment compared to treatment initiation, 4 acquired stable sitting. Six type 1 children were <18 months-old at treatment initiation. Two of them did not need ventilation or nutritional support at the last assessment; three had delayed language development and 3 articulation difficulties. 5/21 SMA type 2 patients achieved higher HFMSE scores. All ambulant type 3 patients showed a gain in the 6MWT. Nusinersen is an effective treatment, with gains in motor function occurring particularly in children and SMA type 1, but also in type 2 and 3, adolescents and adults.

Original language	English
Pages (from-to)	399-409
Number of pages	11
Journal	Neuromuscular Disorders
Volume	32
Issue number	5
Early online date	9 Feb 2022
DOIs	https://doi.org/10.1016/j.nmd.2022.02.001
Publication status	Published - May 2022

Bibliographical note

Funding Information:
This work was supported by a training fellowship of the Swiss Muscle Society to CT Rüsch. A. Klein served on advisory boards of Avexis, Novartis Gene Therapies, Roche and Biogen and received speakers honoraria from Roche and Biogen. D. Jacquier served on advisory boards of Avexis, Novartis Gene Therapies, Roche and Biogen and received speakers honoraria from Biogen. HH Jung served on advisory boards of Biogen and Roche. GM Stettner served on advisory boards of Avexis, Novartis Gene Therapies, Roche and Biogen. Ch. Neuwirth received honoraria for services and advisory board membership from Biogen USA, Biogen Switzerland, Roche, Mitsubishi Tanabe and Sanofi Genzyme. O. Hasselmann received honoraria by Avexis, Novartis Gene Therapies and Biogen following participation on their advisory boards. The Swiss-Reg-NMD receives unconditional from PTC Therapeutics lnternational, Sarepta International, Pfizer Switzerland and Roche Pharma Schweiz AG and research grants from Novartis Gene Therapies and Biogen. None of the funders was involved in the study design, data collection, analysis, interpretation of data or writing the article.

Publisher Copyright:
© 2022 The Authors

Access to Document

10.1016/j.nmd.2022.02.001Licence: CC BY

Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in SwitzerlandFinal published version, 793 KBLicence: CC BY

Cite this

Tscherter, A., Rüsch, C. T., Swiss-Reg-NMD group, Baumann, D., Enzmann, C., Hasselmann, O., Jacquier, D., Jung, H. H., Kruijshaar, M. E., Kuehni, C. E., Neuwirth, C., Stettner, G. M., Klein, A., Lötscher, N., Ramelli, G. P., Ripellino, P., Scheidegger, O., & Wille, D. A. (2022). Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland. Neuromuscular Disorders, 32(5), 399-409. https://doi.org/10.1016/j.nmd.2022.02.001

@article{74a8dfe6a68d43428f6d54d6a54fbae5,

title = "Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland",

abstract = "Spinal muscular atrophy (SMA) is an autosomal recessive disorder causing progressive proximal muscular, respiratory, and bulbar weakness. We present outcome data on motor function, ventilation, nutrition, and language development of SMA patients treated with nusinersen in Switzerland. This multicenter, observational study included 44 patients. At treatment initiation, after 2 months and then every 4 months we assessed motor function with the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP–INTEND), Hammersmith Functional Motor Scale expanded (HFMSE) and 6-Minute Walk Test (6MWT). At treatment initiation, patients were 0.1–44.6 years old, treatment duration ranged from 6 to 41 months. All 11 SMA type 1 children achieved higher CHOP-INTEND scores at the last assessment compared to treatment initiation, 4 acquired stable sitting. Six type 1 children were <18 months-old at treatment initiation. Two of them did not need ventilation or nutritional support at the last assessment; three had delayed language development and 3 articulation difficulties. 5/21 SMA type 2 patients achieved higher HFMSE scores. All ambulant type 3 patients showed a gain in the 6MWT. Nusinersen is an effective treatment, with gains in motor function occurring particularly in children and SMA type 1, but also in type 2 and 3, adolescents and adults.",

author = "Anne Tscherter and R{\"u}sch, {Christina T.} and {Swiss-Reg-NMD group} and Dominique Baumann and Cornelia Enzmann and Oswald Hasselmann and David Jacquier and Jung, {Hans H.} and Kruijshaar, {Michelle E.} and Kuehni, {Claudia E.} and Christoph Neuwirth and Stettner, {Georg M.} and Andrea Klein and Nadine L{\"o}tscher and Ramelli, {Gian P.} and Paolo Ripellino and Oliver Scheidegger and Wille, {David Alexander}",

note = "Funding Information: This work was supported by a training fellowship of the Swiss Muscle Society to CT R{\"u}sch. A. Klein served on advisory boards of Avexis, Novartis Gene Therapies, Roche and Biogen and received speakers honoraria from Roche and Biogen. D. Jacquier served on advisory boards of Avexis, Novartis Gene Therapies, Roche and Biogen and received speakers honoraria from Biogen. HH Jung served on advisory boards of Biogen and Roche. GM Stettner served on advisory boards of Avexis, Novartis Gene Therapies, Roche and Biogen. Ch. Neuwirth received honoraria for services and advisory board membership from Biogen USA, Biogen Switzerland, Roche, Mitsubishi Tanabe and Sanofi Genzyme. O. Hasselmann received honoraria by Avexis, Novartis Gene Therapies and Biogen following participation on their advisory boards. The Swiss-Reg-NMD receives unconditional from PTC Therapeutics lnternational, Sarepta International, Pfizer Switzerland and Roche Pharma Schweiz AG and research grants from Novartis Gene Therapies and Biogen. None of the funders was involved in the study design, data collection, analysis, interpretation of data or writing the article. Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = may,

doi = "10.1016/j.nmd.2022.02.001",

language = "English",

volume = "32",

pages = "399--409",

journal = "Neuromuscular Disorders",

issn = "0960-8966",

publisher = "Elsevier Ltd.",

number = "5",

}

Tscherter, A, Rüsch, CT, Swiss-Reg-NMD group, Baumann, D, Enzmann, C, Hasselmann, O, Jacquier, D, Jung, HH, Kruijshaar, ME, Kuehni, CE, Neuwirth, C, Stettner, GM, Klein, A, Lötscher, N, Ramelli, GP, Ripellino, P, Scheidegger, O & Wille, DA 2022, 'Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland', Neuromuscular Disorders, vol. 32, no. 5, pp. 399-409. https://doi.org/10.1016/j.nmd.2022.02.001

TY - JOUR

T1 - Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland

AU - Tscherter, Anne

AU - Rüsch, Christina T.

AU - Swiss-Reg-NMD group

AU - Baumann, Dominique

AU - Enzmann, Cornelia

AU - Hasselmann, Oswald

AU - Jacquier, David

AU - Jung, Hans H.

AU - Kruijshaar, Michelle E.

AU - Kuehni, Claudia E.

AU - Neuwirth, Christoph

AU - Stettner, Georg M.

AU - Klein, Andrea

AU - Lötscher, Nadine

AU - Ramelli, Gian P.

AU - Ripellino, Paolo

AU - Scheidegger, Oliver

AU - Wille, David Alexander

N1 - Funding Information: This work was supported by a training fellowship of the Swiss Muscle Society to CT Rüsch. A. Klein served on advisory boards of Avexis, Novartis Gene Therapies, Roche and Biogen and received speakers honoraria from Roche and Biogen. D. Jacquier served on advisory boards of Avexis, Novartis Gene Therapies, Roche and Biogen and received speakers honoraria from Biogen. HH Jung served on advisory boards of Biogen and Roche. GM Stettner served on advisory boards of Avexis, Novartis Gene Therapies, Roche and Biogen. Ch. Neuwirth received honoraria for services and advisory board membership from Biogen USA, Biogen Switzerland, Roche, Mitsubishi Tanabe and Sanofi Genzyme. O. Hasselmann received honoraria by Avexis, Novartis Gene Therapies and Biogen following participation on their advisory boards. The Swiss-Reg-NMD receives unconditional from PTC Therapeutics lnternational, Sarepta International, Pfizer Switzerland and Roche Pharma Schweiz AG and research grants from Novartis Gene Therapies and Biogen. None of the funders was involved in the study design, data collection, analysis, interpretation of data or writing the article. Publisher Copyright: © 2022 The Authors

PY - 2022/5

Y1 - 2022/5

N2 - Spinal muscular atrophy (SMA) is an autosomal recessive disorder causing progressive proximal muscular, respiratory, and bulbar weakness. We present outcome data on motor function, ventilation, nutrition, and language development of SMA patients treated with nusinersen in Switzerland. This multicenter, observational study included 44 patients. At treatment initiation, after 2 months and then every 4 months we assessed motor function with the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP–INTEND), Hammersmith Functional Motor Scale expanded (HFMSE) and 6-Minute Walk Test (6MWT). At treatment initiation, patients were 0.1–44.6 years old, treatment duration ranged from 6 to 41 months. All 11 SMA type 1 children achieved higher CHOP-INTEND scores at the last assessment compared to treatment initiation, 4 acquired stable sitting. Six type 1 children were <18 months-old at treatment initiation. Two of them did not need ventilation or nutritional support at the last assessment; three had delayed language development and 3 articulation difficulties. 5/21 SMA type 2 patients achieved higher HFMSE scores. All ambulant type 3 patients showed a gain in the 6MWT. Nusinersen is an effective treatment, with gains in motor function occurring particularly in children and SMA type 1, but also in type 2 and 3, adolescents and adults.

AB - Spinal muscular atrophy (SMA) is an autosomal recessive disorder causing progressive proximal muscular, respiratory, and bulbar weakness. We present outcome data on motor function, ventilation, nutrition, and language development of SMA patients treated with nusinersen in Switzerland. This multicenter, observational study included 44 patients. At treatment initiation, after 2 months and then every 4 months we assessed motor function with the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP–INTEND), Hammersmith Functional Motor Scale expanded (HFMSE) and 6-Minute Walk Test (6MWT). At treatment initiation, patients were 0.1–44.6 years old, treatment duration ranged from 6 to 41 months. All 11 SMA type 1 children achieved higher CHOP-INTEND scores at the last assessment compared to treatment initiation, 4 acquired stable sitting. Six type 1 children were <18 months-old at treatment initiation. Two of them did not need ventilation or nutritional support at the last assessment; three had delayed language development and 3 articulation difficulties. 5/21 SMA type 2 patients achieved higher HFMSE scores. All ambulant type 3 patients showed a gain in the 6MWT. Nusinersen is an effective treatment, with gains in motor function occurring particularly in children and SMA type 1, but also in type 2 and 3, adolescents and adults.

UR - http://www.scopus.com/inward/record.url?scp=85127311122&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2022.02.001

DO - 10.1016/j.nmd.2022.02.001

M3 - Article

C2 - 35337708

AN - SCOPUS:85127311122

SN - 0960-8966

VL - 32

SP - 399

EP - 409

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

IS - 5

ER -

Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this